# Valganciclovir for Treatment of Cytomegalovirus Infection in Solid Organ Transplant Patients

> **NCT00730769** · PHASE4 · COMPLETED · sponsor: **Salvador Gil-Vernet** · enrollment: 21 (actual)

## Conditions studied

- Cytomegalovirus Infection

## Interventions

- **DRUG:** Single arm (ganciclovir and valganciclovir)

## Key facts

- **NCT ID:** NCT00730769
- **Lead sponsor:** Salvador Gil-Vernet
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-03
- **Primary completion:** 2007-07
- **Final completion:** 2008-07
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2011-09-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00730769

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00730769, "Valganciclovir for Treatment of Cytomegalovirus Infection in Solid Organ Transplant Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00730769. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*